Klaria Pharma Holding AB (publ.) (KLAR.ST)
Stockholm · SEK · Healthcare · Drug Manufacturers - Specialty & Generic
SEK 0.532 (-0.37%) as of
Key statistics
- Market cap
- 130.86M
- EPS (TTM)
- -0.1600
- Dividend yield
- 0.00%
- 52-week range
- 0.4500 – 1.3300
- Beta
- 1.29
- Revenue (TTM)
- 100k
- Profit margin
- 0.00%
- Volume
- 789.79k
About Klaria Pharma Holding AB (publ.)
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is based in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Uppsala, Sweden
- Employees
- 4
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.